Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The FDA’s advisory panel voted in opposition to expanded use of Talzenna/Xtandi for prostate most cancers and UGN-102 for recurrent bladder most cancers,...
JAK inhibitors ease myelofibrosis signs however not the illness itself; newer therapies like Ojjaara goal to enhance anemia and provide higher high quality...
From left: GAYLE S. JAMESON, M.S.N, ACNP-BC, AOCN, and ERIN PIERCE, M.S.N., APRN, FNP-C; PHOTOS BY AZULA RAUNGayle S. Jameson, M.S.N, ACNP-BC, AOCN,...
